Buy Avodart online with a free prescription consultation. Go here to order now. 

GI198745 or Dutasteride as we now call it is a new drug developed by GlaxoSmithKline to treat BPH or Benign Prostatic Hyperplasia (enlarged prostate) and MPB, Male Pattern Baldness.
Since DHT is the cause of both of these conditions, the drug works by preventing the DHT from being created in the first place. The 5 alpha reductase enzyme is responsible for turning Testosterone in Dihydrotestosterone (DHT), and the drug works by preventing this chemical change from taking place.
The reason why this drug is so important is that it inhibits both 5-AR type 1 and 5 AR type 2, unlike Propecia (Finasteride), which inhibits just type 2.
It is believed that type 1 is still responsible for about 20% of the DHT that is not eliminated by Propecia and may be the reason why some men do not respond to Propecia, which only inhibits type 2.
Clinical Results
These are the results of the GlaxoSmithKline testing of GI198745 otherwise known as Dutasteride for hair loss. These results were taken from the Phase II study required for FDA approval. The Phase III trials for hair loss are currently on hold, though the FDA recently approved Avodart to treat BPH.. 
These are the results of the GlaxoSmithKline testing of GI198745 otherwise known as Dutasteride for hair loss. These results were taken from the Phase II study required for FDA approval. The Phase III trials for hair loss are currently on hold, but the NDA (New Drug Application) for BPH was submitted to the FDA in December 2000. This mean that if approved by the FDA, Dutasteride could be available by the end of 2001 or early 2002 for the treatment of an enlarged prostate or BPH.

Clinical Results

These are the results of the GlaxoSmithKline testing of GI198745 otherwise known as Dutasteride for hair loss. These results were taken from the Phase II study required for FDA approval. The Phase III trials for hair loss are currently on hold, though the FDA recently approved Avodart to treat BPH.. 
These are the results of the GlaxoSmithKline testing of GI198745 otherwise known as Dutasteride for hair loss. These results were taken from the Phase II study required for FDA approval. The Phase III trials for hair loss are currently on hold, but the NDA (New Drug Application) for BPH was submitted to the FDA in December 2000. This mean that if approved by the FDA, Dutasteride could be available by the end of 2001 or early 2002 for the treatment of an enlarged prostate or BPH.

Week 0                            Week 24

The graph below shows that after six month of treatment the hair counts measured in a 1 inch diameter circle increased by about ~96 hairs with 0.5mg Dutasteride, compared to about ~72 hairs with 5mg Finasteride. The hair counts increased significantly with an increase in dosage with the biggest gain being ~108 hairs with a dose of 2.5mg Dutasteride. So compared to 5mg Finasteride (Propecia), 2.5 mg Dutasteride grew about 1.5 times as many hairs.